Prabhat Bhargava

547 total citations
63 papers, 267 citations indexed

About

Prabhat Bhargava is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Prabhat Bhargava has authored 63 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 32 papers in Surgery and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Prabhat Bhargava's work include Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Gastric Cancer Management and Outcomes (11 papers). Prabhat Bhargava is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (16 papers), Pancreatic and Hepatic Oncology Research (13 papers) and Gastric Cancer Management and Outcomes (11 papers). Prabhat Bhargava collaborates with scholars based in India, Australia and Belgium. Prabhat Bhargava's co-authors include Anant Ramaswamy, Vikas Ostwal, Sujay Srinivas, Vikas Ostwal, Sudeep Gupta, Shripad Banavali, Shraddha Patkar, Mahesh Goel, Sadhana Kannan and Jyoti Bajpai and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Prabhat Bhargava

50 papers receiving 262 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Prabhat Bhargava India 10 120 87 85 42 36 63 267
Chérifa Taleb France 8 115 1.0× 84 1.0× 55 0.6× 22 0.5× 21 0.6× 19 281
Guo-yue Lv China 5 134 1.1× 54 0.6× 68 0.8× 46 1.1× 16 0.4× 6 296
David Hughes United States 7 96 0.8× 50 0.6× 40 0.5× 25 0.6× 49 1.4× 32 324
Hwee Leong Tan Singapore 12 128 1.1× 120 1.4× 244 2.9× 56 1.3× 30 0.8× 41 404
L. Carbone Italy 10 87 0.7× 120 1.4× 134 1.6× 21 0.5× 26 0.7× 32 275
Şener Cihan Türkiye 10 145 1.2× 66 0.8× 57 0.7× 24 0.6× 29 0.8× 40 247
Yazan Abboud United States 9 125 1.0× 43 0.5× 97 1.1× 65 1.5× 27 0.8× 60 281
Luca Giraldi Italy 12 78 0.7× 63 0.7× 98 1.2× 77 1.8× 64 1.8× 28 432
Andrea Gillis United States 10 95 0.8× 59 0.7× 109 1.3× 55 1.3× 29 0.8× 73 305
James R. Ouellette United States 9 208 1.7× 88 1.0× 134 1.6× 18 0.4× 11 0.3× 21 326

Countries citing papers authored by Prabhat Bhargava

Since Specialization
Citations

This map shows the geographic impact of Prabhat Bhargava's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prabhat Bhargava with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prabhat Bhargava more than expected).

Fields of papers citing papers by Prabhat Bhargava

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prabhat Bhargava. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prabhat Bhargava. The network helps show where Prabhat Bhargava may publish in the future.

Co-authorship network of co-authors of Prabhat Bhargava

This figure shows the co-authorship network connecting the top 25 collaborators of Prabhat Bhargava. A scholar is included among the top collaborators of Prabhat Bhargava based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prabhat Bhargava. Prabhat Bhargava is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chandrasekharan, Arun, Bharat Rekhi, Prabhat Bhargava, et al.. (2025). Vascular endothelial growth factor: A potential prognosticator in Ewing sarcoma. Indian Journal of Cancer. 62(3). 345–354. 1 indexed citations
2.
3.
Bhandare, Manish, Subhash Yadav, Vikas Ostwal, et al.. (2024). CA 19-9 Surveillance Detects Recurrences Early and Contributes to Improvement in Survival in Resected Ampullary Cancers. Annals of Surgery. 283(2). 286–296. 1 indexed citations
4.
Bhargava, Prabhat, Anant Ramaswamy, Avanish Saklani, et al.. (2024). Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD—High Study). JCO Global Oncology. 10(10). e2400141–e2400141. 2 indexed citations
5.
Bajpai, Jyoti, Gaurav Gupta, Bharat Rekhi, et al.. (2024). Evaluation of Metronomic Therapy as a Low-Cost, Sustainable, Standard-of-Care Option in Desmoid Fibromatosis: Real-World Data From a Tertiary Care Center in India. JCO Global Oncology. 10(10). e2300308–e2300308.
6.
Chaudhari, Vikram, Vikas Ostwal, Anant Ramaswamy, et al.. (2024). Evolution and improved outcomes in the era of multimodality treatment for extended pancreatectomy. BJS Open. 8(4).
7.
Ramaswamy, Anant, Prabhat Bhargava, S. Srinivas, et al.. (2024). Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial. Journal of Clinical Oncology. 42(27). 3218–3227. 1 indexed citations
8.
Bhargava, Prabhat, et al.. (2024). Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers. SHILAP Revista de lepidopterología. 13(4). 296–299. 1 indexed citations
9.
10.
11.
Ramaswamy, Anant, Anand V. Kulkarni, George John, et al.. (2023). Survival of Trial-Like and Non–Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP). JCO Global Oncology. 9(9). e2300215–e2300215. 4 indexed citations
12.
Ostwal, Vikas, Prabhat Bhargava, S. Srinivas, et al.. (2023). Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB). Journal of Clinical Oncology. 42(7). 800–807. 20 indexed citations
13.
Bhargava, Prabhat, et al.. (2023). Chemotherapy-Induced Alopecia: Can We Measure the Level of Distress in Oncology Patients? (The ALDO Study). SHILAP Revista de lepidopterología. 12(4). 390–393. 1 indexed citations
14.
Kazi, Mufaddal, Mahesh Goel, Avanish Saklani, et al.. (2023). Feasibility of Hepatic Artery Infusion Chemotherapy for Colorectal Liver Metastasis in an Indian Setting. Indian Journal of Surgical Oncology. 15(S2). 275–280. 1 indexed citations
15.
Bhargava, Prabhat, Vikas Ostwal, Sujay Srinivas, et al.. (2023). Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.. Journal of Clinical Oncology. 41(16_suppl). e16168–e16168.
16.
Ostwal, Vikas, Anant Ramaswamy, Prabhat Bhargava, et al.. (2021). Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open. 11(6). e047376–e047376. 26 indexed citations
17.
Bajpai, Jyoti, Aparna Chatterjee, Akhil Kapoor, et al.. (2020). 429P Demographics, pattern of care, and outcome analysis of malignant melanoma cases from a tertiary care centre in India. Annals of Oncology. 31. S1410–S1410. 1 indexed citations
18.
Bhargava, Prabhat, et al.. (2019). Outcomes of gastrointestinal tumours in the tyrosine kinase inhibitor era: 15 years of experience from a single tertiary care centre in India. Annals of Oncology. 30. iv87–iv87. 1 indexed citations
19.
Ostwal, Vikas, Anant Ramaswamy, Alok Goel, et al.. (2018). Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. Indian Journal of Cancer. 55(2). 144–144. 2 indexed citations
20.
Prabhash, Kumar, Saurabh Zanwar, Amit Joshi, et al.. (2016). Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis. Indian Journal of Cancer. 53(4). 579–579. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chérifa Taleb Breakdown of academic impact, for papers by Guo-yue Lv Breakdown of academic impact, for papers by David Hughes Breakdown of academic impact, for papers by Hwee Leong Tan Breakdown of academic impact, for papers by L. Carbone Breakdown of academic impact, for papers by Şener Cihan Breakdown of academic impact, for papers by Yazan Abboud Breakdown of academic impact, for papers by Luca Giraldi Breakdown of academic impact, for papers by Andrea Gillis Breakdown of academic impact, for papers by James R. Ouellette
Rankless by CCL
2026